Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

In the treatment of patients with IgA nephropathy, the use of sibeprenlimab, a humanized IgG2 monoclonal antibody that binds to and neutralizes a proliferation-inducing ligand (APRIL), appears to lead to a significant reduction in proteinuria, according to a phase II trial.

Sibeprenlimab shows promise in IgA nephropathy

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

The glucagon/GLP-1 receptor dual agonist survodutide appears to be safe and induce weight loss in individuals with obesity, according to data from a phase II dose-finding trial.

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

10 Feb 2024

Treatment with the anti-influenza A virus inhibitor onradivir is safe and leads to symptom improvement and viral load reduction in adults with uncomplicated influenza infection, according to data from a phase II trial.

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

10 Feb 2024

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

07 Feb 2024

Treatment with erdafitinib or pembrolizumab results in similar median overall survival (OS) in pretreated patients with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor (FGFR) alterations (FGFRalt), a study has shown. Safety results are also comparable to the known profiles for both regimens in this patient population.

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

07 Feb 2024

Elevated INR predicts mortality in DOAC-treated patients

Among hospitalized patients treated with direct oral anticoagulants (DOACs), an elevated international normalized ratio (INR) upon admission may spell an increased risk for in-hospital death or mortality during the first year following hospitalization, suggests a study.

Elevated INR predicts mortality in DOAC-treated patients

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

06 Feb 2024 bởi

In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

06 Feb 2024

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

Babies born to mothers who were exposed to low-dose aspirin during pregnancy do not appear to have altered neurodevelopmental outcomes at age 3 years, according to a study.

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain

Ketamine is noninferior to morphine in terms of providing pain relief in patients with out-of-hospital traumatic pain, according to the results of the KETAMORPH* study.

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain

Evinacumab hits mark in difficult-to-treat children with rare lipid disorder

05 Feb 2024 bởi

The angiopoietin-like 3 inhibitor evinacumab appears to reduce low-density lipoprotein cholesterol (LDL-C) levels in children with homozygous familial hypercholesterolemia (HoFH) and persistently high LDL-C despite optimized therapy.

Evinacumab hits mark in difficult-to-treat children with rare lipid disorder

Sitra + nivo slightly better than docetaxel in advanced NSCLC